Xeris Biopharma Holdings Inc (XERS)
3.07
+0.03
(+0.99%)
USD |
NASDAQ |
Nov 22, 15:04
Xeris Biopharma Holdings Gross Profit Margin (Quarterly): 74.95% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 74.95% |
| June 30, 2024 | 83.79% |
| March 31, 2024 | 85.31% |
| December 31, 2023 | 82.95% |
| September 30, 2023 | 83.03% |
| June 30, 2023 | 80.12% |
| March 31, 2023 | 83.98% |
| December 31, 2022 | 81.02% |
| September 30, 2022 | 82.30% |
| June 30, 2022 | 80.99% |
| March 31, 2022 | 71.58% |
| December 31, 2021 | 77.19% |
| September 30, 2021 | 70.89% |
| June 30, 2021 | 62.01% |
| March 31, 2021 | 77.72% |
| Date | Value |
|---|---|
| December 31, 2020 | 53.77% |
| September 30, 2020 | 69.89% |
| June 30, 2020 | 35.92% |
| March 31, 2020 | -6.80% |
| December 31, 2019 | 14.00% |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | 84.03% |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | 99.29% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-6.80%
Minimum
Mar 2020
85.31%
Maximum
Mar 2024
67.23%
Average
77.45%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Zevra Therapeutics Inc | 37.67% |
| NovaBay Pharmaceuticals Inc | 65.26% |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -19.24% |
| Return on Invested Capital | -31.15% |
| Profit Margin (Quarterly) | -29.00% |
| Operating Margin (Quarterly) | -23.76% |
| Return on Net Operating Assets | -26.16% |